The proposed model enables automated and interpretable assessment of MASLD-related fibrosis staging from digital liver biopsy histopathology and provides a quantitative tool for pathology phenotype-based risk stratification. Further clinical translation requires integration of clinical risk factors and validation in longitudinal outcome-based frameworks.
Pan et al. (Mon,) studied this question.